search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Corporate Profile


Abcam: experts in advanced proteomic and cellular tools and technologies


A


bcam is a global company that identifies, develops and distributes high-quality biological reagents,


proteomic and cellular tools that are crucial to research, drug discovery and diagnostics. Working across the healthcare and life sci- ence industries, Abcam supports the grow- ing needs of the industry by collaborating with expert organisations to co-create novel binders and other proteomic tools for use in drug discovery, in vitro diagnostics and therapeutics, relying on the Company’s pro- prietary discovery platforms and world- leading, antibody expertise. By constantly innovating its binders and


assays, Abcam helps to advance the global understanding of biology and causes of dis- ease to enable new treatments and improved health. In addition to more than 20 years of pro-


teomic and cellular tools expertise, Abcam has been focused on expanding its antibody conjugation and labelling capabilities as these continue to be of growing importance within the life sciences industry, with up to 84% of researchers seeking conjugation-ready solu- tions1. This includes molecular labels that are covalently attached to a protein of interest to facilitate detection, or the purification of a protein or its binding partners. Abcam’s recent acquisition of Expedeon’s proteomics technology and


portfolio introduces key labelling plat- forms incorporating enzymes, metals, oli- gos and fluorescent proteins. Combining proprietary capture and conjugation tech- nologies such as Lightning-Link® with Abcam’s extensive antibody and protein expertise will expand and enhance its port- folio of off-the-shelf and custom reagents and tools, while creating new value-added products that can support diagnostic and therapeutic development. Abcam’s recent partnership with BrickBio is also poised to provide new con- jugation tools. With the unique ability to incorporate unnatural amino acids acting as controlled conjugation sites, the anti- body can be coupled to a second molecule in a quantitative manner, enabling precise labelling. In addition, the proprietary tech- nology can be used to create protein-conju- gate therapeutics including antibody-drug- conjugates (ADCs). Delivering payloads to cells can also be


useful in research and diagnostic applica- tions and Abcam has recently joined forces with SomaServe to commercialise the cell delivery potential of polymer-based


PolyNaut® ‘bionic’ nanoparticles. These nanoparticles can carry a range of payloads directly to live cells. Abcam and SomaServe are developing the delivery and assay options of the platform, including optimis- ing its potential with antibodies and other technologies. Abcam has always been dedicated to providing scientists with industry-leading technology and the highest-quality reagents, and fully supports initiatives that improve reproducibility across the life sci- ence sector. It has helped address the cur- rent reproducibility crisis related to poor quality reagents including antibodies2, by driving in-house antibody validation through knockout (KO) cell line testing. To date, more than 2,500 antibodies have been tested by Abcam – an unprecedented scale within the industry. Abcam’s antibody validation initiative is supported further by the recent launch of its KO cell lysates and cell lines, the largest available portfolio on the market providing validated positive and negative control samples for antibody validation. The cell lines can also be used in the study of bio- logical pathways and disease models, as well as screening and cellular assays includ- ing high-throughput applications. Abcam’s industry knowledge and insight


drives its innovation and partnership strat- egy. Its aim is to build collaborations focused on value-added solutions and flex- ible commercial structures that maximise project success and tackle key challenges in the life sciences. To date, it has delivered more than 3,000 custom projects. Through active collaboration with the industry and its partners, Abcam develops tools that are critical to progressing areas of unmet medical need, to ultimately help improve global human health.


References 1 Abcam proprietary data. 2 Bradbury, A et al (2015). Reproducibility: Standardize antibodies used in research. Nature. 518(7537): pp 27-9.


32 Drug Discovery World Winter 2019/20


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68